Valuation: UCB

Market Cap 42.21B 48.57B 39.41B 36.18B 68.22B 4,630B 69.41B 465B 182B 2,309B 182B 178B 7,615B P/E 2026 *
22.6x
P/E 2027 * 18.4x
Enterprise Value 42.33B 48.71B 39.52B 36.28B 68.42B 4,643B 69.61B 466B 183B 2,315B 183B 179B 7,637B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 4.16x
Free-Float
61.59%
Yield 2026 *
0.66%
Yield 2027 * 0.68%
1 day-2.16%
1 week-8.34%
Current month-2.16%
1 month-14.22%
3 months-2.22%
6 months-16.81%
Current year-10.13%
1 week 259.59
Extreme 259.59
295.59
1 month 259.59
Extreme 259.59
302.09
Current year 259.59
Extreme 259.59
345.39
1 year 211.48
Extreme 211.48
345.39
3 years 69.7
Extreme 69.7
345.39
5 years 68.3
Extreme 68.3011
345.39
10 years 58.42
Extreme 58.42
345.39
Manager TitleAgeSince
Chief Executive Officer 67 01/01/2015
Director of Finance/CFO 60 01/07/2020
Chief Tech/Sci/R&D Officer 59 01/05/2024
Director TitleAgeSince
Director/Board Member 55 01/01/2012
Director/Board Member 67 01/01/2015
Director/Board Member 56 24/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%-8.34% - - 48.89B
-0.44%+13.80%+35.85%-1.58% 76.15B
-4.18%+42.30%+42.30%+42.30% 47.83B
+2.18%+6.18%-52.09%-52.13% 41.37B
-0.56%+0.84%+52.95%-24.62% 29.99B
-0.91%-0.37%+56.67%+82.26% 24.23B
+0.58%-0.88%+99.75%-49.85% 21.89B
-0.81%-3.75%-7.53%+162.20% 19.25B
-7.35%-6.03%+64.90%+113.10% 17.14B
-0.16%-4.95%+68.80%+149.10% 15.66B
Average -1.39%+0.81%+40.18%+46.75% 32.61B
Weighted average by Cap. -1.23%+3.00%+33.35%+24.88%

Financials

2026 *2027 *
Net sales 8.62B 9.92B 8.05B 7.39B 13.93B 945B 14.17B 94.87B 37.16B 471B 37.25B 36.42B 1,555B 9.68B 11.14B 9.04B 8.3B 15.65B 1,062B 15.92B 107B 41.74B 530B 41.84B 40.92B 1,747B
Net income 1.85B 2.12B 1.72B 1.58B 2.98B 203B 3.04B 20.33B 7.96B 101B 7.98B 7.8B 333B 2.33B 2.68B 2.17B 1.99B 3.76B 255B 3.82B 25.61B 10.03B 127B 10.05B 9.83B 420B
Net Debt 122M 140M 114M 104M 197M 13.35B 200M 1.34B 525M 6.66B 526M 515M 21.97B -1.98B -2.28B -1.85B -1.7B -3.2B -217B -3.26B -21.81B -8.54B -108B -8.56B -8.37B -357B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
03/08/26 $263.84 -2.16% 48
31/07/26 $269.66 +3.88% 49
30/07/26 $259.59 -12.18% 86
29/07/26 $295.59 +5.38% 7,620
28/07/26 $280.49 -2.55% 853
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
221.40EUR
Average target price
286.11EUR
Spread / Average Target
+29.23%

Quarterly revenue - Rate of surprise